Objective To investigate the mechanism by which astragaloside IV alleviates renal fibrosis in unilateral ureteral obstruction (UUO) rats by inhibiting ferroptosis through modulation of the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) signaling pathway. Methods Specific pathogen-free (SPF) male Sprague-Dawley (SD) rats were used to establish UUO models and randomly divided into four groups (n=6 per group): sham operation group, model group, AS-IV group [40 mg/(kg·d)], and losartan group [10.3 mg/(kg·d)]. Intragastric administration began one day post-surgery and continued for 14 days. Serum creatinine (Scr), blood urea nitrogen (BUN), and cAMP levels were measured. Renal histopathology was assessed via hematoxylin-eosin (HE) and Masson staining. Immunohistochemistry evaluated fibrosis markers [α-smooth muscle actin (α-SMA), fibronectin (FN), collagen type I (COL-I)], while Western blotting analyzed PKA and ferroptosis-related markers [glutathione peroxidase 4 (GPX4), heme oxygenase-1 (HO-1), solute carrier family 7 member 11 (xCT)]. Results No significant differences in Scr were observed among groups (F=2.815, P=0.065). Compared to the sham group, the model group exhibited elevated BUN (t=26.306, P＜0.001), which was reduced in the astragaloside IV and losartan potassium groups (t=−5.241, −3.469; P＜0.001, P=0.002, respectively). HE and Masson staining revealed severe renal fibrosis in the obstructed kidneys of rats in the model group, while fibrosis was attenuated in the astragaloside IV and losartan potassium groups. Compared with the sham operation group, the model group exhibited increased expression of α-SMA, FN, COL-I (t =17.728, 9.202, 13.710, all P＜0.001), cAMP levels (t =9.601, P＜0.001), and PKA (t =32.321, P＜0.001). In the astragaloside IV and losartan potassium groups, the expression of α-SMA (t =-11.457, -5.519, P＜0.001, P =0.001), FN (t =-6.301, -4.725, P＜0.001, P =0.001), COL-I (t =-6.087, -3.243, P＜0.001, P=0.012), cAMP levels (t =-6.629,-5.809, both P＜0.001), and PKA (t =-22.754, -23.294, both P＜0.001) was decreased compared with the model group. Compared with the sham operation group, the model group showed decreased expression of GPX4, HO-1, and xCT (t =-38.397, -41.713, -56.779, all P＜0.001). In the astragaloside IV and losartan potassium groups, the expression of GPX4 (t =25.504, 16.786, both P＜0.001), HO-1 (t=10.611, 42.007, both P＜0.001), and xCT (t=7.192, 3.181, P＜0.001, P =0.013) was increased compared with the model group. Conclusions Astragaloside IV improves renal function and mitigates fibrosis in UUO rats, potentially by suppressing ferroptosis through regulation of the cAMP/PKA signaling pathway.
HE Xiao-Dan
,
ZHANG Zi-Yuan
,
HU Ya-Ling
,
FANG Jing-Ai
. Astragaloside IV alleviates renal fibrosis in unilateral ureteral obstruction rats by inhibiting ferroptosis through the regulation of the cAMP/PKA signaling pathway[J]. Chinese Journal of Blood Purification, 2025
, 24(06)
: 479
-484
.
DOI: 10.3969/j.issn.1671-4091.2025.06.008
[1] Francis A, Harhay M N, Ong A, et al. Chronic kidney disease and the global public health agenda: an international consensus[J]. Nature Reviews Nephrology, 2024: 1-13.
[2] Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. The lancet, 2012, 379(9818): 815-822.
[3] Ruiz-Ortega M, Rayego-Mateos S, Lamas S, et al. Targeting the progression of chronic kidney disease[J]. Nature Reviews Nephrology, 2020, 16(5): 269-288.
[4] 赖玮婧,黄蓉双,王波等.肾脏病中铁死亡的病理生理机制和药物疗法研究进展[J].中华肾脏病杂志,2024,40(5):411-417.
[5] Li D, Liu Y, Zhan Q, et al. Astragaloside IV Blunts Epithelial–Mesenchymal Transition and G2/M Arrest to Alleviate Renal Fibrosis via Regulating ALDH2-Mediated Autophagy[J]. Cells, 2023, 12(13): 1777.
[6] Zhou X, Sun X, Gong X, et al. Astragaloside IV from Astragalus membranaceus ameliorates renal interstitial fibrosis by inhibiting inflammation via TLR4/NF-кB in vivo and in vitro[J]. International Immunopharmacology, 2017, 42: 18-24.
[7] Wang X, Gao Y, Tian N, et al. Astragaloside IV improves renal function and fibrosis via inhibition of miR-21-induced podocyte dedifferentiation and mesangial cell activation in diabetic mice[J]. Drug design, development and therapy, 2018: 2431-2442.
[8] Weng L, Wang W, Su X, et al. The effect of cAMP-PKA activation on TGF-β1-induced profibrotic signaling[J]. Cellular Physiology and Biochemistry, 2015, 36(5): 1911-1927.
[9] Delrue C, Speeckaert R, Moresco R N, et al. Cyclic Adenosine Monophosphate Signaling in Chronic Kidney Disease: Molecular Targets and Therapeutic Potentials[J]. International Journal of Molecular Sciences, 2024, 25(17): 9441.
[10] 黄倩,张素萍,施子禄.人参多糖通过cAMP/PKA/CREB信号通路抗糖尿病肾病肾纤维化作用机制研究[J].中国药理学通报,2018,34(05):695-701.
[11] Guan Q, Wang Z, Hu K, et al. Melatonin ameliorates hepatic ferroptosis in NAFLD by inhibiting ER stress via the MT2/cAMP/PKA/IRE1 signaling pathway[J]. International journal of biological sciences, 2023, 19(12): 3937.
[12] Huang R, Fu P, Ma L. Kidney fibrosis: from mechanisms to therapeutic medicines[J]. Signal Transduction and Targeted Therapy, 2023, 8(1): 129.
[13] Li L, He M, Tang X, et al. Proteomic landscape of the extracellular matrix in the fibrotic kidney[J]. Kidney International, 2023, 103(6): 1063-1076.
[14] Song Y, Liu W, Tang K, et al. Mangiferin Alleviates Renal Interstitial Fibrosis in Streptozotocin‐Induced Diabetic Mice through Regulating the PTEN/PI3K/Akt Signaling Pathway[J]. Journal of Diabetes Research, 2020, 2020(1): 9481720.
[15] Dixon S J, Lemberg K M, Lamprecht M R, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death[J]. cell, 2012, 149(5): 1060-1072.
[16] Dodson M, Castro-Portuguez R, Zhang D D. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis[J]. Redox biology, 2019, 23: 101107.
[17] Lane D J R, Metselaar B, Greenough M, et al. Ferroptosis and NRF2: an emerging battlefield in the neurodegeneration of Alzheimer's disease[J]. Essays in Biochemistry, 2021, 65(7): 925-940.
[18] Adedoyin O, Boddu R, Traylor A, et al. Heme oxygenase-1 mitigates ferroptosis in renal proximal tubule cells[J]. American Journal of Physiology-Renal Physiology, 2018, 314(5): F702-F714.
[19] Kwon M Y, Park E, Lee S J, et al. Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death[J]. Oncotarget, 2015, 6(27): 24393.
[20] Tu H, Tang L J, Luo X J, et al. Insights into the novel function of system Xc-in regulated cell death[J]. European Review for Medical & Pharmacological Sciences, 2021, 25(3).
[21] Seibt T M, Proneth B, Conrad M. Role of GPX4 in ferroptosis and its pharmacological implication[J]. Free Radical Biology and Medicine, 2019, 133: 144-152.
[22] Meng X, Nikolic-Paterson D J, Lan H Y. TGF-β: the master regulator of fibrosis[J]. Nature Reviews Nephrology, 2016, 12(6): 325-338.
[23] Delrue C, Speeckaert R, Moresco R N, et al. Cyclic Adenosine Monophosphate Signaling in Chronic Kidney Disease: Molecular Targets and Therapeutic Potentials[J]. International Journal of Molecular Sciences, 2024, 25(17): 9441.
[24] Deb D K, Bao R, Li Y C. Critical role of the cAMP-PKA pathway in hyperglycemia-induced epigenetic activation of fibrogenic program in the kidney[J]. The FASEB Journal, 2017, 31(5): 2065.
[25] Zhang L, Liu W, Li S, et al. Astragaloside IV alleviates renal fibrosis by inhibiting renal tubular epithelial cell pyroptosis induced by urotensin II through regulating the cAMP/PKA signaling pathway[J]. Plos one, 2024, 19(5): e0304365.
